Jacobio Pharma Secures RMB 200 Million Strategic Partnership with Oceanpine Capital to Advance KRAS Oncology Pipeline
核心洞察
Jacobio Pharma (搜索) announced a strategic partnership with Oceanpine Capital (搜索), with the investment firm acquiring 80% equity interest in Jacoray for RMB 200 million to support oncology innovation.
The transaction involves divesting Jacobio's early-stage cardiovascular (搜索) research program while maintaining focus on developing innovative oncology therapies including KRAS (搜索) and iADC (搜索) platforms.
Proceeds from the partnership will primarily support R&D, production, and commercialization of Jacobio's Pan-KRAS inhibitor (搜索) and other oncology assets across global markets.
Jacobio Pharma (搜索) (1167.HK) has announced a strategic partnership with Oceanpine Capital (搜索) that will provide RMB 200 million in funding to accelerate the development of its core oncology pipeline, particularly focusing on KRAS (搜索) pathway inhibitors and innovative antibody-drug conjugates (iADC (搜索)).
Strategic Transaction Structure
Under the Capital Increase and Equity Transfer Agreement announced on October 15, 2025, Oceanpine Capital (搜索) will acquire an 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. (搜索) (Jacoray) for a total consideration of RMB 200 million. The payment structure includes RMB 125 million as an upfront payment and an additional RMB 75 million as a second installment milestone payment. Upon completion, Beijing Jacobio will retain a 10% stake in Jacoray, with Oceanpine Capital holding 80% and an industry partner maintaining the remaining 10%.
Jacoray serves as the project company for Jacobio's early-stage cardiovascular (搜索) research program. The transaction represents a strategic pivot that allows Jacobio to optimize capital allocation by divesting non-core assets while maintaining focus on its oncology innovation platform.
Focus on Oncology Innovation
The partnership aligns with Jacobio's strategic emphasis on developing innovative oncology therapies, including KRAS (搜索) and iADC (搜索) platforms. Proceeds from the transaction will primarily support research and development, production, and commercialization of Jacobio's Pan-KRAS inhibitor (搜索) and other oncology assets.
Jacobio operates with an induced allosteric drug discovery platform, with core projects focusing on the KRAS (搜索) pathway. The company maintains R&D centers in Beijing, Shanghai, and Boston, conducting clinical trials at over 180 sites in China, more than 30 sites in the United States, and over 10 sites across several European countries.
Leadership Perspectives
Dave Chenn, Founder, CEO and Managing Partner of Oceanpine Capital (搜索), emphasized the strategic value of the partnership: "Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China's biotech innovation."
Dr. Yinxiang Wang, Chairman of Jacobio, highlighted the transaction's strategic importance: "This partnership with Oceanpine Capital (搜索) strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer (搜索) therapies."
Investment Partner Profile
Oceanpine Capital (搜索), founded in 2018, operates as a professional investment management firm dedicated to long-term value investing. The firm focuses on cutting-edge sectors including advanced technology, green technology, and life sciences, with assets under management exceeding RMB 25 billion. The partnership represents Oceanpine's continued commitment to driving technological innovation in the biotechnology sector.
The transaction adopts a risk-sharing model designed to retain long-term project value while enhancing operational efficiency for Jacobio's core oncology development programs.